Antisense oligonucleotides demonstrated positive results in preclinical models; for example, early studies with antisense inhibition of PKCα demonstrated that it enhanced the antitumor effects of cisplatin in subcutaneously injected H460 cells [401], and additional studies showed that it significantly impaired nonsmall cell lung cancer tumor growth [402]. Here, PRKCA is linked to neoplasm.